CRM 107

Known as: CRM-107, CRM107 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1987-2006
01219872006

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2007
2007
Transferrin (Tf) conjugates of CRM107 are currently being tested in clinical trials for treatment of malignant gliomas. However… (More)
Is this relevant?
Review
2006
Review
2006
Despite the progress of the bioinformatics approach to characterize cell-surface antigens and receptors on tumor cells, it… (More)
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
1998
1998
Previously a mathematical model was proposed that quantitatively related protein synthesis inhibition kinetics of antitransferrin… (More)
Is this relevant?
1997
1997
Bispecific antibodies were designed to deliver a reversibly bound ligand into target cells and then spontaneously release it upon… (More)
Is this relevant?
1994
1994
Targeted protein toxins are a new class of reagents with the potential for great tumor selectivity and cytotoxic potency. Two… (More)
Is this relevant?
1994
1994
We have evaluated the sensitivity to immunotoxins (IT) of monolayer and of 200-250 microns multicellular tumor spheroid (MTS… (More)
Is this relevant?
1990
1990
CRM107 (crossreacting material 107), a double point mutant of diphtheria toxin that lacks receptor-binding activity, specifically… (More)
Is this relevant?
1987
1987
Monoclonal antibodies linked to toxic proteins (immunotoxins) can selectively kill some tumor cells in vitro and in vivo. However… (More)
Is this relevant?